Viridian Therapeutics, Inc.\DE— Sankey Diagram
Quarterly mode · period ending 2025-12-31 · SEC EDGAR
ComparingFY2025 (Q4) vs FY2024 (Q4)
Revenue
$132K
↑+83.3% +$60Kvs FY2024 (Q4)
Gross Profit
$132K
↑+83.3% +$60Kvs FY2024 (Q4)
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 (Q4) | FY2024 (Q4) |
|---|---|---|
| Revenue | $132K | $72K |
| COGS | $0 | $0 |
| Gross Profit | $132K | $72K |
| R&D | $89M | $72M |
| SG&A | $0 | $0 |
| D&A | $120K | $123K |
| Other OpEx | $0 | $0 |
| Operating Income | $0 | $0 |
| Interest Exp. | $0 | $0 |
| Other Non-Op | $0 | $0 |
| Pretax Income | $0 | $0 |
| Tax | $0 | $0 |
| Net Income | $0 | $0 |
QuarterCharts · SEC EDGAR data · VRDN · Comparing FY2025 (Q4) vs FY2024 (Q4)